trending Market Intelligence /marketintelligence/en/news-insights/trending/uhazptyzedvw4mr9bddhka2 content esgSubNav
In This List

Amneal Pharmaceuticals repurchases $599.4M of senior notes via cash tender offer

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Amneal Pharmaceuticals repurchases $599.4M of senior notes via cash tender offer

Amneal Pharmaceuticals Inc. repurchased its 2.00% senior convertible notes due 2022 through a cash tender offer.

The New Jersey-based generic drugmaker's recently acquired unit, Impax Laboratories LLC, conducted the offer. Impax said about $599.4 million of notes were tendered, representing about 99.9% of the outstanding notes.

RBC Capital Markets acted as dealer manager for the offer.